Board of Directors

Peter Keeling (age 58), Chief Executive Officer
Peter has over 30 years’ experience as a leader, entrepreneur and strategist in the pharmaceutical industry. He has led international companies and teams with a focus on novel business models and product launches, including therapies, diagnostics and FMCG products.

Peter started his career as Distribution Manager at American Monitor Corporation where he oversaw the distribution of reagents and equipment globally. He subsequently spent 11 years leading projects in both operational and strategic roles at the pharmaceutical division of the Wellcome Foundation, including Sales Manager for the pharmaceutical business in North and West Africa (4 years), Commercial Director for a joint venture with Wellcome Indonesia (3.5 years) and Brand Director at a global product level for Wellcome’s antiviral franchise (3.5 years). Wellcome was merged into Glaxo in 2004. Subsequently, he was Founder and Chief Executive Officer of Diagnology Inc, a US/Irish based diagnostics company which specialised in development and commercialisation of tests for sexually transmitted diseases. Peter has led Diaceutics from its inception in 2005 to become a leader in innovative solutions which currently services 20 of the world’s largest pharmaceutical companies.

Peter holds a degree in business administration from Queens University Belfast, a Masters degree in European Marketing from Buckingham University Business School and spent an academic year as a Visiting Fellow at MIT’s Sloan business school in 1994 where he led a multi-corporation US think tank designed to look at disruptive healthcare models for the pharma industry. Peter has published several peer reviewed papers on precision medicine and is a respected speaker at precision medicine events around the world.

Ryan Keeling (age 36), Chief Innovation Officer
Ryan is an expert in commercialisation of diagnostics and associated technology, with over 10 years’ experience in the field.

Ryan has led the development and commercialisation of the Group’s technology, including its proprietary data lake. Ryan has played a pivotal role in the Group’s technological and strategic development, previously acting as its Chief Operating Officer until June 2018. As CIO, Ryan is responsible for driving the Group’s product innovation, with a near term focus on the development of NEXUS. Prior to joining Diaceutics in 2009, Ryan spent eight years as a software engineer for Aepona Limited, providing network infrastructure and related services to telecommunications operators.

Ryan holds a software engineering degree from Queens University Belfast. Ryan is seen as a thought leader in the field of diagnostic commercialisation and data integration speaking at precision medicine and healthcare data conferences globally.

Philip White FCA (age 44), Chief Financial Officer
Philip has over 15 years’ management and financial experience, and has been Chief Financial Officer of Diaceutics since 2011.

He is a fellow member of the Institute of Chartered Accountants in Ireland and of the Institute of Directors. Philip gained a degree in Law and Accountancy from Queens University Belfast, and has completed the SEP program at the London Business School. Prior to joining Diaceutics, Philip was involved in negotiation, execution and integration of corporate acquisitions through his role as director of Philip White Tyres Ltd. a family business. Philip has responsibility for all financial and risk management operations and works with the executive management team to develop and implement strategies across the organisation.

Julie Goonewardene Wallin (age 60), Non-Executive Chair
Julie joined the advisory board of Diaceutics in 2013 and was appointed Chairperson in 2019. She has extensive experience in healthcare, information technology, and business.

Having graduated from Purdue University, she spent the first twenty years of her career in the field of information technology, leading the growth and exit of companies in the sector. In 2005, she returned to Purdue to create the University’s first venture fund and to help faculty inventors turn their research projects into commercial enterprises. Julie then went on to remake the corporate partnership and commercialisation capabilities at the University of Kansas and University of Kansas Medical Center.

She currently serves as the Chief Innovation and Human Resources Officer at the University of Texas System, which is one of the US’s largest and most respected systems of higher education with a focus on healthcare.

Her board experience includes American Medical Association (immediate past public member), and the Personalized Medicine Coalition (immediate past member). Additionally, she served as an advisor to the United States Secretary of Commerce as a member of the U.S. Department of Commerce’s National Advisory Council on Innovation and Entrepreneurship (NACIE). She was also a member of the American Association for the Advancement of Science (AAAS) Committee on Science, Engineering and Public Policy.

Charles Hindson (age 59), Non-Executive Director
Charles joins the board as a non-executive director, and chair of the audit and remuneration committees. He brings 16 years’ experience of FTSE listed company board membership, having served in executive director roles with Filtronic plc, firstly as Group Finance Director and subsequently Chief Executive, and then with e2v technologies plc, as Group Finance Director.

He is experienced in supporting business leaders develop technology businesses internationally, through organic growth and successful acquisitions, and this has been reflected in creating meaningful shareholder value with these listed companies.

His early career was with 3i and PwC, and then in HQ and international divisional finance roles with British Gas plc and British Telecom plc before becoming Finance Director with Eutelsat SA, based in Paris, France. He now also serves as a trustee of Trinity College London, the international exam board for performing arts and English language qualifications, and is a member of its audit committee.

Michael Wort (age 68), Non-Executive Director
Having trained as a microbiologist, Michael brings over 40 years’ experience working with life science companies across the healthcare sector. Initially working with three of the top ten global pharmaceutical companies in a variety of sales, marketing and research positions, he was appointed Investor Relations Manager of Wellcome Plc and was actively involved in the global communications programme for the major £2.3 billion secondary offering of Wellcome Plc shares by the Wellcome Trust, which enabled him to develop working relationships with key figures in the life sciences industry.

After leaving Wellcome, Michael was a founding partner in the UK’s first specialist communications agency, for the emerging biotechnology industry. Apart from a diversion caused by his involvement as the CEO during the privatisation of the Bulgarian pharmaceutical industry his career has been devoted to working with start-up and growing SMEs to maximise their potential for growth.

Latest Corporate News / RNS Announcements

Latest Corporate News / RNS Announcements

Investor Alerts